Synthetic cannabinoid JWH-018 and psychosis: An explorative study

Abstract Background Aroma, Spice, K2 and Dream are examples of a class of new and increasingly popular recreational drugs. Ostensibly branded “herbal incense”, they have been intentionally adulterated with synthetic cannabinoids such as JWH-018 in order to confer on them cannabimimetic psychoactive...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug and alcohol dependence 2011-09, Vol.117 (2), p.152-157
1. Verfasser: Every-Palmer, Susanna
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 157
container_issue 2
container_start_page 152
container_title Drug and alcohol dependence
container_volume 117
creator Every-Palmer, Susanna
description Abstract Background Aroma, Spice, K2 and Dream are examples of a class of new and increasingly popular recreational drugs. Ostensibly branded “herbal incense”, they have been intentionally adulterated with synthetic cannabinoids such as JWH-018 in order to confer on them cannabimimetic psychoactive properties while circumventing drug legislation. JWH-018 is a potent cannabinoid receptor agonist. Little is known about its pharmacology and toxicology in humans. This is the first research considering the effects of JWH-018 on a psychiatric population and exploring the relationship between JWH-018 and psychotic symptoms. Method This paper presents the results of semi-structured interviews regarding the use and effects of JWH-018 in 15 patients with serious mental illness in a New Zealand forensic and rehabilitative service. Results All 15 subjects were familiar with a locally available JWH-018 containing product called “Aroma” and 86% reported having used it. They credited the product's potent psychoactivity, legality, ready availability and non-detection in drug testing as reasons for its popularity, with most reporting it had replaced cannabis as their drug of choice. Most patients had assumed the product was “natural” and “safe”. Anxiety and psychotic symptoms were common after use, with 69% of users experiencing or exhibiting symptoms consistent with psychotic relapse after smoking JWH-018. Although psychological side effects were common, no one reported becoming physically unwell after using JWH-018. Three subjects described developing some tolerance to the product, but no one reported withdrawal symptoms. Conclusion It seems likely that JWH-018 can precipitate psychosis in vulnerable individuals. People with risk factors for psychosis should be counseled against using synthetic cannabinoids.
doi_str_mv 10.1016/j.drugalcdep.2011.01.012
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_902097083</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0376871611000639</els_id><sourcerecordid>1093441292</sourcerecordid><originalsourceid>FETCH-LOGICAL-c622t-d07ab15fe6bc2edfa1f00b47897bbd484c839359e8cbc9032afd41490d5e6efb3</originalsourceid><addsrcrecordid>eNqNkk1v1DAQQCMEotvCX0C5ILhkmXGyjs0BaakoBVXiUBBHy7En1EvWSe2kIv8eR7tQiQNgjeTLmw_7TZblCGsE5K92axumb7ozloY1A8Q1LMEeZCsUtSwAKv4wW0FZ80LUyE-y0xh3kA6X8Dg7YVgiR85W2fZ69uMNjc7kRnuvG-d7Z_OPXy8LQJFrb_Mhzuamjy6-zrc-px9D1wc9ujvK4zjZ-Un2qNVdpKfH-yz7cvHu8_llcfXp_Yfz7VVhOGNjYaHWDW5a4o1hZFuNLUBT1ULWTWMrURlRynIjSZjGSCiZbm2FlQS7IU5tU55lLw51h9DfThRHtXfRUNdpT_0UlQQGsgZRJvLlX0ms09s3jKP4NwqyrCpkkiVUHFAT-hgDtWoIbq_DnCC1WFE7dW9FLVYULLGkPjt2mZo92d-JvzQk4PkR0NHorg3aGxfvuWWESvLEvT1wlD76zlFQ0TjyhqwLZEZle_c_07z5o4jpnHep73eaKe76KfgkUqGKTIG6XrZoWSLEZX-SpJ-pD8MV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1093441292</pqid></control><display><type>article</type><title>Synthetic cannabinoid JWH-018 and psychosis: An explorative study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><creator>Every-Palmer, Susanna</creator><creatorcontrib>Every-Palmer, Susanna</creatorcontrib><description>Abstract Background Aroma, Spice, K2 and Dream are examples of a class of new and increasingly popular recreational drugs. Ostensibly branded “herbal incense”, they have been intentionally adulterated with synthetic cannabinoids such as JWH-018 in order to confer on them cannabimimetic psychoactive properties while circumventing drug legislation. JWH-018 is a potent cannabinoid receptor agonist. Little is known about its pharmacology and toxicology in humans. This is the first research considering the effects of JWH-018 on a psychiatric population and exploring the relationship between JWH-018 and psychotic symptoms. Method This paper presents the results of semi-structured interviews regarding the use and effects of JWH-018 in 15 patients with serious mental illness in a New Zealand forensic and rehabilitative service. Results All 15 subjects were familiar with a locally available JWH-018 containing product called “Aroma” and 86% reported having used it. They credited the product's potent psychoactivity, legality, ready availability and non-detection in drug testing as reasons for its popularity, with most reporting it had replaced cannabis as their drug of choice. Most patients had assumed the product was “natural” and “safe”. Anxiety and psychotic symptoms were common after use, with 69% of users experiencing or exhibiting symptoms consistent with psychotic relapse after smoking JWH-018. Although psychological side effects were common, no one reported becoming physically unwell after using JWH-018. Three subjects described developing some tolerance to the product, but no one reported withdrawal symptoms. Conclusion It seems likely that JWH-018 can precipitate psychosis in vulnerable individuals. People with risk factors for psychosis should be counseled against using synthetic cannabinoids.</description><identifier>ISSN: 0376-8716</identifier><identifier>EISSN: 1879-0046</identifier><identifier>DOI: 10.1016/j.drugalcdep.2011.01.012</identifier><identifier>PMID: 21316162</identifier><identifier>CODEN: DADEDV</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Addictive behaviors ; Adult ; Adult and adolescent clinical studies ; Anxiety ; Aroma ; Biological and medical sciences ; Cannabinoid receptors ; Cannabinoids ; Cannabinoids - adverse effects ; Cannabinoids - pharmacology ; Cannabis ; Designer drugs ; Dreams ; Drug abuse ; Drug addiction ; Drug dependence ; Drug tolerance ; Forensic psychiatry ; Forensic science ; Humans ; incense ; Indoles - adverse effects ; Indoles - pharmacology ; Interview, Psychological ; JWH-018 ; Legislation ; Male ; Medical sciences ; Mental disorders ; Middle Aged ; Naphthalenes - adverse effects ; Naphthalenes - pharmacology ; New Zealand ; Pharmacology ; Popularity ; Psychiatry ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychoses ; Psychoses, substance-induced ; Psychoses, Substance-Induced - epidemiology ; Psychosis ; Psychotic disorders ; Psychotic Disorders - complications ; Psychotic Disorders - epidemiology ; Psychotic symptoms ; Qualitative research ; Receptor, Cannabinoid, CB1 - agonists ; Receptor, Cannabinoid, CB2 - agonists ; Relapse ; Risk factors ; Side effects ; Smoking ; Spice ; Spices ; Street Drugs - adverse effects ; Street Drugs - pharmacology ; Substance-Related Disorders - epidemiology ; Withdrawal ; Withdrawal symptoms ; Young Adult</subject><ispartof>Drug and alcohol dependence, 2011-09, Vol.117 (2), p.152-157</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2011 Elsevier Ireland Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c622t-d07ab15fe6bc2edfa1f00b47897bbd484c839359e8cbc9032afd41490d5e6efb3</citedby><cites>FETCH-LOGICAL-c622t-d07ab15fe6bc2edfa1f00b47897bbd484c839359e8cbc9032afd41490d5e6efb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.drugalcdep.2011.01.012$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,30981,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=24412496$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21316162$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Every-Palmer, Susanna</creatorcontrib><title>Synthetic cannabinoid JWH-018 and psychosis: An explorative study</title><title>Drug and alcohol dependence</title><addtitle>Drug Alcohol Depend</addtitle><description>Abstract Background Aroma, Spice, K2 and Dream are examples of a class of new and increasingly popular recreational drugs. Ostensibly branded “herbal incense”, they have been intentionally adulterated with synthetic cannabinoids such as JWH-018 in order to confer on them cannabimimetic psychoactive properties while circumventing drug legislation. JWH-018 is a potent cannabinoid receptor agonist. Little is known about its pharmacology and toxicology in humans. This is the first research considering the effects of JWH-018 on a psychiatric population and exploring the relationship between JWH-018 and psychotic symptoms. Method This paper presents the results of semi-structured interviews regarding the use and effects of JWH-018 in 15 patients with serious mental illness in a New Zealand forensic and rehabilitative service. Results All 15 subjects were familiar with a locally available JWH-018 containing product called “Aroma” and 86% reported having used it. They credited the product's potent psychoactivity, legality, ready availability and non-detection in drug testing as reasons for its popularity, with most reporting it had replaced cannabis as their drug of choice. Most patients had assumed the product was “natural” and “safe”. Anxiety and psychotic symptoms were common after use, with 69% of users experiencing or exhibiting symptoms consistent with psychotic relapse after smoking JWH-018. Although psychological side effects were common, no one reported becoming physically unwell after using JWH-018. Three subjects described developing some tolerance to the product, but no one reported withdrawal symptoms. Conclusion It seems likely that JWH-018 can precipitate psychosis in vulnerable individuals. People with risk factors for psychosis should be counseled against using synthetic cannabinoids.</description><subject>Addictive behaviors</subject><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Anxiety</subject><subject>Aroma</subject><subject>Biological and medical sciences</subject><subject>Cannabinoid receptors</subject><subject>Cannabinoids</subject><subject>Cannabinoids - adverse effects</subject><subject>Cannabinoids - pharmacology</subject><subject>Cannabis</subject><subject>Designer drugs</subject><subject>Dreams</subject><subject>Drug abuse</subject><subject>Drug addiction</subject><subject>Drug dependence</subject><subject>Drug tolerance</subject><subject>Forensic psychiatry</subject><subject>Forensic science</subject><subject>Humans</subject><subject>incense</subject><subject>Indoles - adverse effects</subject><subject>Indoles - pharmacology</subject><subject>Interview, Psychological</subject><subject>JWH-018</subject><subject>Legislation</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mental disorders</subject><subject>Middle Aged</subject><subject>Naphthalenes - adverse effects</subject><subject>Naphthalenes - pharmacology</subject><subject>New Zealand</subject><subject>Pharmacology</subject><subject>Popularity</subject><subject>Psychiatry</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychoses</subject><subject>Psychoses, substance-induced</subject><subject>Psychoses, Substance-Induced - epidemiology</subject><subject>Psychosis</subject><subject>Psychotic disorders</subject><subject>Psychotic Disorders - complications</subject><subject>Psychotic Disorders - epidemiology</subject><subject>Psychotic symptoms</subject><subject>Qualitative research</subject><subject>Receptor, Cannabinoid, CB1 - agonists</subject><subject>Receptor, Cannabinoid, CB2 - agonists</subject><subject>Relapse</subject><subject>Risk factors</subject><subject>Side effects</subject><subject>Smoking</subject><subject>Spice</subject><subject>Spices</subject><subject>Street Drugs - adverse effects</subject><subject>Street Drugs - pharmacology</subject><subject>Substance-Related Disorders - epidemiology</subject><subject>Withdrawal</subject><subject>Withdrawal symptoms</subject><subject>Young Adult</subject><issn>0376-8716</issn><issn>1879-0046</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNqNkk1v1DAQQCMEotvCX0C5ILhkmXGyjs0BaakoBVXiUBBHy7En1EvWSe2kIv8eR7tQiQNgjeTLmw_7TZblCGsE5K92axumb7ozloY1A8Q1LMEeZCsUtSwAKv4wW0FZ80LUyE-y0xh3kA6X8Dg7YVgiR85W2fZ69uMNjc7kRnuvG-d7Z_OPXy8LQJFrb_Mhzuamjy6-zrc-px9D1wc9ujvK4zjZ-Un2qNVdpKfH-yz7cvHu8_llcfXp_Yfz7VVhOGNjYaHWDW5a4o1hZFuNLUBT1ULWTWMrURlRynIjSZjGSCiZbm2FlQS7IU5tU55lLw51h9DfThRHtXfRUNdpT_0UlQQGsgZRJvLlX0ms09s3jKP4NwqyrCpkkiVUHFAT-hgDtWoIbq_DnCC1WFE7dW9FLVYULLGkPjt2mZo92d-JvzQk4PkR0NHorg3aGxfvuWWESvLEvT1wlD76zlFQ0TjyhqwLZEZle_c_07z5o4jpnHep73eaKe76KfgkUqGKTIG6XrZoWSLEZX-SpJ-pD8MV</recordid><startdate>20110901</startdate><enddate>20110901</enddate><creator>Every-Palmer, Susanna</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7QJ</scope></search><sort><creationdate>20110901</creationdate><title>Synthetic cannabinoid JWH-018 and psychosis: An explorative study</title><author>Every-Palmer, Susanna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c622t-d07ab15fe6bc2edfa1f00b47897bbd484c839359e8cbc9032afd41490d5e6efb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Addictive behaviors</topic><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Anxiety</topic><topic>Aroma</topic><topic>Biological and medical sciences</topic><topic>Cannabinoid receptors</topic><topic>Cannabinoids</topic><topic>Cannabinoids - adverse effects</topic><topic>Cannabinoids - pharmacology</topic><topic>Cannabis</topic><topic>Designer drugs</topic><topic>Dreams</topic><topic>Drug abuse</topic><topic>Drug addiction</topic><topic>Drug dependence</topic><topic>Drug tolerance</topic><topic>Forensic psychiatry</topic><topic>Forensic science</topic><topic>Humans</topic><topic>incense</topic><topic>Indoles - adverse effects</topic><topic>Indoles - pharmacology</topic><topic>Interview, Psychological</topic><topic>JWH-018</topic><topic>Legislation</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mental disorders</topic><topic>Middle Aged</topic><topic>Naphthalenes - adverse effects</topic><topic>Naphthalenes - pharmacology</topic><topic>New Zealand</topic><topic>Pharmacology</topic><topic>Popularity</topic><topic>Psychiatry</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychoses</topic><topic>Psychoses, substance-induced</topic><topic>Psychoses, Substance-Induced - epidemiology</topic><topic>Psychosis</topic><topic>Psychotic disorders</topic><topic>Psychotic Disorders - complications</topic><topic>Psychotic Disorders - epidemiology</topic><topic>Psychotic symptoms</topic><topic>Qualitative research</topic><topic>Receptor, Cannabinoid, CB1 - agonists</topic><topic>Receptor, Cannabinoid, CB2 - agonists</topic><topic>Relapse</topic><topic>Risk factors</topic><topic>Side effects</topic><topic>Smoking</topic><topic>Spice</topic><topic>Spices</topic><topic>Street Drugs - adverse effects</topic><topic>Street Drugs - pharmacology</topic><topic>Substance-Related Disorders - epidemiology</topic><topic>Withdrawal</topic><topic>Withdrawal symptoms</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Every-Palmer, Susanna</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><jtitle>Drug and alcohol dependence</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Every-Palmer, Susanna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synthetic cannabinoid JWH-018 and psychosis: An explorative study</atitle><jtitle>Drug and alcohol dependence</jtitle><addtitle>Drug Alcohol Depend</addtitle><date>2011-09-01</date><risdate>2011</risdate><volume>117</volume><issue>2</issue><spage>152</spage><epage>157</epage><pages>152-157</pages><issn>0376-8716</issn><eissn>1879-0046</eissn><coden>DADEDV</coden><abstract>Abstract Background Aroma, Spice, K2 and Dream are examples of a class of new and increasingly popular recreational drugs. Ostensibly branded “herbal incense”, they have been intentionally adulterated with synthetic cannabinoids such as JWH-018 in order to confer on them cannabimimetic psychoactive properties while circumventing drug legislation. JWH-018 is a potent cannabinoid receptor agonist. Little is known about its pharmacology and toxicology in humans. This is the first research considering the effects of JWH-018 on a psychiatric population and exploring the relationship between JWH-018 and psychotic symptoms. Method This paper presents the results of semi-structured interviews regarding the use and effects of JWH-018 in 15 patients with serious mental illness in a New Zealand forensic and rehabilitative service. Results All 15 subjects were familiar with a locally available JWH-018 containing product called “Aroma” and 86% reported having used it. They credited the product's potent psychoactivity, legality, ready availability and non-detection in drug testing as reasons for its popularity, with most reporting it had replaced cannabis as their drug of choice. Most patients had assumed the product was “natural” and “safe”. Anxiety and psychotic symptoms were common after use, with 69% of users experiencing or exhibiting symptoms consistent with psychotic relapse after smoking JWH-018. Although psychological side effects were common, no one reported becoming physically unwell after using JWH-018. Three subjects described developing some tolerance to the product, but no one reported withdrawal symptoms. Conclusion It seems likely that JWH-018 can precipitate psychosis in vulnerable individuals. People with risk factors for psychosis should be counseled against using synthetic cannabinoids.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>21316162</pmid><doi>10.1016/j.drugalcdep.2011.01.012</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0376-8716
ispartof Drug and alcohol dependence, 2011-09, Vol.117 (2), p.152-157
issn 0376-8716
1879-0046
language eng
recordid cdi_proquest_miscellaneous_902097083
source MEDLINE; Elsevier ScienceDirect Journals; Applied Social Sciences Index & Abstracts (ASSIA)
subjects Addictive behaviors
Adult
Adult and adolescent clinical studies
Anxiety
Aroma
Biological and medical sciences
Cannabinoid receptors
Cannabinoids
Cannabinoids - adverse effects
Cannabinoids - pharmacology
Cannabis
Designer drugs
Dreams
Drug abuse
Drug addiction
Drug dependence
Drug tolerance
Forensic psychiatry
Forensic science
Humans
incense
Indoles - adverse effects
Indoles - pharmacology
Interview, Psychological
JWH-018
Legislation
Male
Medical sciences
Mental disorders
Middle Aged
Naphthalenes - adverse effects
Naphthalenes - pharmacology
New Zealand
Pharmacology
Popularity
Psychiatry
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychoses
Psychoses, substance-induced
Psychoses, Substance-Induced - epidemiology
Psychosis
Psychotic disorders
Psychotic Disorders - complications
Psychotic Disorders - epidemiology
Psychotic symptoms
Qualitative research
Receptor, Cannabinoid, CB1 - agonists
Receptor, Cannabinoid, CB2 - agonists
Relapse
Risk factors
Side effects
Smoking
Spice
Spices
Street Drugs - adverse effects
Street Drugs - pharmacology
Substance-Related Disorders - epidemiology
Withdrawal
Withdrawal symptoms
Young Adult
title Synthetic cannabinoid JWH-018 and psychosis: An explorative study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T03%3A13%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synthetic%20cannabinoid%20JWH-018%20and%20psychosis:%20An%20explorative%20study&rft.jtitle=Drug%20and%20alcohol%20dependence&rft.au=Every-Palmer,%20Susanna&rft.date=2011-09-01&rft.volume=117&rft.issue=2&rft.spage=152&rft.epage=157&rft.pages=152-157&rft.issn=0376-8716&rft.eissn=1879-0046&rft.coden=DADEDV&rft_id=info:doi/10.1016/j.drugalcdep.2011.01.012&rft_dat=%3Cproquest_cross%3E1093441292%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1093441292&rft_id=info:pmid/21316162&rft_els_id=S0376871611000639&rfr_iscdi=true